Canine Leptospirosis Market size is expected to reach USD 6 Billion by the end of 2036, expanding around 6% CAGR during the forecast period i.e., 2024-2036. In the year 2023, the industry size of canine leptospirosis was over 900 Million. The growth of this market can be primarily driven by the increased prevalence of infectious leptospirosis globally. Furthermore, the increasing transfer of infection from animals to humans is boosting the growth of the market. A study published in the journal Pathogen in March 2022 found that leptospirosis infection in humans is one of the leading and neglected causes of morbidity and mortality, with more than 1 million cases per year and approximately 60,000 people being found dead.
The global pet ownership is on the rise, with more and more people welcoming dogs into their families. This expanding pet population spreads to a larger pool of potential candidates for leptospirosis vaccination and treatment as a result driving the market growth of the canine leptospirosis market in the projected time period.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~6% |
|
Base Year Market Size (2023) |
~USD 900 Million |
|
Forecast Year Market Size (2036) |
~USD 6 Billion |
|
Regional Scope |
|
By Drug Type (Doxycycline, Penicillin, Ampicillin, Pfizerpen)
Based on drug type, the penicillin segment is predicted to dominate the canine leptospirosis market by registering a CAGR of 40% by the end of 2036. The segment growth in the forecast period is supported by the benefits of penicillin treatment over alternative treatments, as well as growing availability on the market. In research studies conducted, the effectiveness of penicillin against leptospirosis infection was considered to be highly effective and is expected to bring about greater awareness among patients as well as increased use of penicillin for the management of leptospirosis infections in order to support segment growth. In particular, early penicillin therapy appears to be effective and can minimize the risk of multiple organ failure as a result of leptospirosis by up to 80 % according to research presented at Membrane in March 2022.
Distribution Channel (Veterinary Hospital Pharmacies, Veterinary Clinics, Retail Pharmacies, Drugstores, Online Pharmacies)
Canine leptospirosis market from the veterinary hospital pharmacies segment is predicted to hold the highest revenue growth of 40% by the end of 2036. Collaboration between vet hospitals and pharmaceutical companies could facilitate research and development of innovative leptospirosis vaccines and therapeutics, ultimately benefitting the market. Furthermore, the integration of technology solutions such as inventory management systems, and electronic health records can streamline operations, enhance inventory visibility, and personalize recommendations for pet owners, enhancing the overall pharmacy experience. Besides, veterinarians can directly recommend and dispense suitable antibiotics and supportive medications for diagnosed cases, ensuring quick treatment initiation. Also, veterinary hospitals can maintain optimal inventory levels of commonly used leptospirosis medications, ensuring immediate availability for their patients. Additionally, veterinary pharmacists can provide additional information and guidance to pet owners on medication administration, side effects, and follow-up care. All these are the significant factors considered behind the segment growth of veterinary hospital pharmacies in the market in the studied period.
Our in-depth analysis of the global canine leptospirosis market includes the following segments:
|
Drug Type |
|
|
Route of Administration |
|
|
Distribution Channel |
|
North American Market Forecasts
The canine leptospirosis market in the North America region is set to hold the largest market share of 35% by the end of 2036. Regional market growth has been projected to be boosted by the presence of drug manufacturers. There are also important animals in the region that have been linked to the zoonotic disease of leptospirosis. This will result in more demand for leptospirosis diagnosis and treatment, stimulating the development of the region's market. Indeed, in the U.S. between 63 % and 66 % of households representing 86.9 million homes had a pet as of 2023 according to estimates provided by the American Pet Products Association 2024. Furthermore, according to Pet Keen's data of May 2023, Canada has the biggest proportion of cat and dog owners in all developed countries with cats accounting for over 38% of households and dogs around 35%.
Europe Market Statistics
The canine leptospirosis market in the Europe region is set to hold a significant revenue share during the time period between 2024-2036. The growth of this market in the region can be attributed on the back of increasing investment in research and development activities. Furthermore, growing urbanization leads to increased contact between dogs and potential sources of leptospirosis bacteria, such as rats and contaminated water. Climate change and extreme events such as floods can also exacerbate the spread of the bacteria, creating new vulnerabilities for canine populations. This is set to accelerate the market growth in this region in the review period.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?